Abstract

BackgroundDespite the use of pneumococcal vaccines, indigenous populations are consistently disproportionately affected by invasive pneumococcal disease (IPD). With recent changes in Ontario’s provincial pneumococcal vaccination program, we sought to evaluate the epidemiology and burden of IPD in northwestern Ontario (NWO) Canada – a region that contains a substantial (19.2%) indigenous population.MethodsWe retrospectively reviewed all adult cases of IPD that were reported to the Thunder Bay District Health Unit, in Thunder Bay, Ontario, Canada, over a 10-year period (2006–2015). Patients admitted to the Thunder Bay Regional Health Sciences Centre with IPD had their charts reviewed to abstract clinical data. Statistical analysis, including incidence rates of IPD, was performed.ResultsTwo hundred sixty-two cases of IPD occurred over the 10-year observation period and clinical data was available for 182 cases. Fifty-three of 182 (29.1%) patients were indigenous. 73 of 182 (40.1%) of patients were immunocompromised. Indigenous patients with IPD were more likely to be immunocompromised than non-indigenous patients (p < 0.001). Serotype data was available for 159 cases of IPD; PCV7, PCV13, and PPV23 covered 5.7%, 28.3%, and 79.2% of isolates, respectively, while 29 (20.8%) were non-vaccine serotypes. The annual incidence rate of IPD ranged from 8.9 to 25.9 per 100,000 among adults 18–64 years old; among adults 65 years of age and older the annual incidence of IPD ranged from 18.5 to 60.7 per 100,000.ConclusionAmong adults in NWO, Canada, there is a high incidence of IPD. Immunocompromised indigenous adults in NWO may benefit from pneumococcal vaccination coverage. Emerging non-vaccine serotypes of Streptococcus pneumoniae warrant the consideration of the provincial pneumococcal vaccination program.

Highlights

  • Despite the use of pneumococcal vaccines, indigenous populations are consistently disproportionately affected by invasive pneumococcal disease (IPD)

  • Over the 10-year period (2006–2015), 262 adult cases of IPD were reported to public health (TBDHU) and had age, gender, year of isolation, and serotype data. 182 of the 262 cases (69.5%) involved patients hospitalized at the Thunder Bay Regional Health Sciences Centre (TBRHSC) and had complete clinical and demographic data available

  • We found that indigenous patients hospitalized at the TBRHSC with IPD were statistically more likely to be immunocompromised than non-indigenous patients

Read more

Summary

Introduction

Despite the use of pneumococcal vaccines, indigenous populations are consistently disproportionately affected by invasive pneumococcal disease (IPD). Dalcin et al BMC Infectious Diseases (2018) 18:621 pneumococcal immunization, additional PPV23 vaccination is currently recommended for individuals ≥24 months of age who have a medical condition or lifestyle risk factor that is considered high risk for IPD [10]. It seems that many Canadians do not receive the recommended pneumococcal immunizations. Statistics Canada estimates that in 2014 only 17.3% (13.7–20.8, 95% CI) of individuals 18–64 years of age with a chronic medical condition where PPV23 is indicated received at least one PPV23 immunization, compared to 36.5% (32.7–40.3, 95% CI) among adults 65 years of age and older [12]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call